ABT-894 + ABT-894 + ABT-894 + placebo + Duloxetine
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Neuralgia
Conditions
Diabetic Neuralgia, Diabetic Neuropathies, Diabetic Neuropathy, Painful, Diabetic Polyneuropathy, Neuralgia, Diabetic
Trial Timeline
Aug 1, 2007 → Oct 1, 2008
NCT ID
NCT00507936About ABT-894 + ABT-894 + ABT-894 + placebo + Duloxetine
ABT-894 + ABT-894 + ABT-894 + placebo + Duloxetine is a phase 2 stage product being developed by AbbVie for Diabetic Neuralgia. The current trial status is completed. This product is registered under clinical trial identifier NCT00507936. Target conditions include Diabetic Neuralgia, Diabetic Neuropathies, Diabetic Neuropathy, Painful.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00507936 | Phase 2 | Completed |
Competing Products
20 competing products in Diabetic Neuralgia